サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1577551

αグルコシダーゼ阻害剤の世界市場

Alpha Glucosidase Inhibitors

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
αグルコシダーゼ阻害剤の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

αグルコシダーゼ阻害剤の世界市場は2030年までに54億米ドルに到達

2023年に47億米ドルと推定されるαグルコシダーゼ阻害剤の世界市場は、2023年から2030年にかけてCAGR 2.3%で成長し、2030年には54億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである病院薬局流通チャネルは、CAGR 2.3%を記録し、分析期間終了時には29億米ドルに達すると予測されます。小売薬局流通チャネルセグメントの成長率は、分析期間中CAGR 2.0%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 4.0％で成長予測

米国のαグルコシダーゼ阻害剤市場は2023年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに10億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1％と2.0％と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界のαグルコシダーゼ阻害剤市場- 主要動向と促進要因のまとめ

αグルコシダーゼ阻害剤は糖尿病治療をどのように形成しているか？

αグルコシダーゼ阻害剤（AGI）は、2型糖尿病の管理に一般的に処方される経口薬の一種です。小腸での糖質吸収を遅延させることにより、AGIは血糖値のコントロールを助け、特に食後のグルコース上昇に対する糖尿病管理に不可欠な薬です。これらの阻害薬は、食事療法と運動療法だけでは血糖コントロールの維持が困難な患者に特に有効です。アカルボース、ミグリトール、ボグリボースは最も一般的に処方されるAGIであり、これらの薬剤は主に北米やアジアなど糖尿病有病率の高い地域の患者を対象としています。糖尿病が世界的に増加していることから、ヘルスケアプロバイダーはこの慢性疾患と闘うための効果的な非インスリン療法を求めており、AGIの需要は今後も増加すると予想されます。

αグルコシダーゼ阻害剤の主要市場セグメントは？

αグルコシダーゼ阻害剤市場は、アカルボース、ミグリトール、ボグリボースなどのタイプ別に区分することができ、アカルボースはその有効性と市場浸透率の長さから最も広く使用されています。エンドユーザーの観点からは、病院、診療所、小売薬局が主要な流通チャネルであり、入手のしやすさと手頃な価格から小売薬局が大きなシェアを占めています。外来診療への注目の高まりと糖尿病の在宅管理へのシフトは、小売薬局セグメントをさらに拡大しています。地域別では、北米が糖尿病有病率の高さと先進的なヘルスケアシステムに牽引されて市場を独占している一方、アジア太平洋地域は糖尿病罹患率の上昇とヘルスケアインフラの拡大に後押しされて急成長を遂げようとしています。

技術とヘルスケアの動向はAGIの使用にどのような影響を与えているか？

糖尿病治療における技術革新は、αグルコシダーゼ阻害剤の使用に大きな影響を与えています。個別化医療がますます重視される中、AGIは個々の患者のプロファイルに合わせた併用療法の一部として処方されています。さらに、継続的グルコースモニタリング（CGM）システムやウェアラブルヘルス技術により、糖尿病のより良い管理が可能になり、患者やヘルスケアプロバイダーがグルコースコントロールのための包括的なソリューションを求めているため、間接的にAGIの需要を押し上げています。スクリーニング技術の向上と公衆衛生意識の高まりにより、2型糖尿病の早期診断が進む動向も、早期介入におけるAGIの使用を拡大し、AGIを総合的な治療計画の不可欠な一部にしています。

αグルコシダーゼ阻害剤市場の成長を促進する要因は？

αグルコシダーゼ阻害剤市場の成長は、特に新興国における2型糖尿病の世界の有病率の上昇など、いくつかの要因によって牽引されています。診断技術の進歩により早期発見が可能になり、AGI治療の対象となる患者数が増加しています。また、患者や医療従事者の間で経口非インスリン療法への嗜好が高まっており、併用療法へのアプローチも増加していることから、市場はさらに拡大しています。さらに、糖尿病合併症に対する意識の高まりと長期的な血糖コントロールの重視が、AGIの採用を後押ししています。アジア太平洋やラテンアメリカのような地域におけるヘルスケアインフラの拡大と、糖尿病管理を目的とした政府の支援政策も、市場の成長を後押ししています。

調査対象企業の例（注目の51社）

  • Abcam PLC
  • Arlak Corazon
  • Astellas Pharma, Inc.
  • Biocon Ltd.
  • Biosynth Ltd.
  • Cipla Ltd.
  • Creative Enzymes
  • Curvio Healthcare
  • Kikkoman Biochemifa Company
  • NARK Pharmaceuticals Pvt. Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24568

Global Alpha Glucosidase Inhibitors Market to Reach US$5.4 Billion by 2030

The global market for Alpha Glucosidase Inhibitors estimated at US$4.7 Billion in the year 2023, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2023-2030. Hospital Pharmacies Distribution Channel, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Retail Pharmacies Distribution Channel segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 4.0% CAGR

The Alpha Glucosidase Inhibitors market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Alpha Glucosidase Inhibitors Market - Key Trends and Drivers Summarized

How Are Alpha Glucosidase Inhibitors Shaping Diabetes Treatment?

Alpha glucosidase inhibitors (AGIs) are a class of oral medications commonly prescribed to manage Type 2 diabetes. By delaying carbohydrate absorption in the small intestine, AGIs help control blood glucose levels, making them essential in diabetes management, especially for postprandial glucose spikes. These inhibitors are particularly effective for patients who struggle to maintain glycemic control through diet and exercise alone. Acarbose, miglitol, and voglibose are the most commonly prescribed AGIs, with their application primarily targeting patients in regions with high diabetes prevalence, such as North America and Asia. Given the global rise in diabetes, the demand for AGIs is expected to continue increasing as healthcare providers seek effective, non-insulin therapies to combat this chronic condition.

What Are the Key Market Segments for Alpha Glucosidase Inhibitors?

The alpha glucosidase inhibitors market can be segmented by type, including acarbose, miglitol, and voglibose, with acarbose being the most widely used due to its long-established effectiveness and market penetration. In terms of end-users, hospitals, clinics, and retail pharmacies are key distribution channels, with retail pharmacies holding a substantial market share due to ease of access and affordability. The growing focus on outpatient care and the shift toward home management of diabetes further expands the retail pharmacy segment. Regionally, North America dominates the market, driven by high diabetes prevalence and advanced healthcare systems, while the Asia-Pacific region is poised for the fastest growth, fueled by rising diabetes rates and expanding healthcare infrastructure.

How Are Technological and Healthcare Trends Impacting AGI Usage?

Innovations in diabetes care are significantly impacting the use of alpha glucosidase inhibitors. With the increasing emphasis on personalized medicine, AGIs are being prescribed as part of combination therapies tailored to individual patient profiles. Additionally, continuous glucose monitoring (CGM) systems and wearable health technologies are allowing for better management of diabetes, indirectly boosting demand for AGIs as patients and healthcare providers seek comprehensive solutions for glucose control. The trend toward earlier diagnosis of Type 2 diabetes, driven by improved screening techniques and increased public health awareness, has also widened the use of AGIs in early-stage interventions, making them an integral part of a holistic treatment plan.

What Factors Are Driving the Growth in the Alpha Glucosidase Inhibitors Market?

The growth in the alpha glucosidase inhibitors market is driven by several factors, including the rising global prevalence of Type 2 diabetes, particularly in emerging economies. Advances in diagnostic technologies are enabling earlier detection, increasing the pool of patients eligible for AGI therapy. The growing preference for oral, non-insulin therapies among patients and healthcare providers, coupled with the rise in combination therapy approaches, is further expanding the market. Additionally, increased awareness of diabetes complications and the emphasis on long-term glycemic control are encouraging the adoption of AGIs. Expanding healthcare infrastructure in regions like Asia-Pacific and Latin America, combined with supportive government policies aimed at diabetes management, are also propelling market growth.

Select Competitors (Total 51 Featured) -

  • Abcam PLC
  • Arlak Corazon
  • Astellas Pharma, Inc.
  • Biocon Ltd.
  • Biosynth Ltd.
  • Cipla Ltd.
  • Creative Enzymes
  • Curvio Healthcare
  • Kikkoman Biochemifa Company
  • NARK Pharmaceuticals Pvt. Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Alpha Glucosidase Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Type 2 Diabetes Drives Demand for Alpha Glucosidase Inhibitors
    • Increased Awareness of Diabetes Management Propels Growth of Antidiabetic Medications
    • Technological Advancements in Drug Delivery Systems Expand Addressable Market for Oral Diabetes Medications
    • Growing Focus on Personalized Medicine Strengthens Business Case for Targeted Diabetes Therapies
    • Expansion of the Geriatric Population Spurs Demand for Diabetes Management Solutions
    • Rising Healthcare Expenditure in Emerging Markets Generates Opportunities for Alpha Glucosidase Inhibitors
    • Advancements in Combination Therapies Propel Growth of Alpha Glucosidase Inhibitor Products
    • Increasing Emphasis on Preventative Care and Early Diagnosis Drives Market Growth
    • Growing Trend Towards Non-Insulin Diabetes Therapies Fuels Adoption of Alpha Glucosidase Inhibitors
    • Demand for Cost-Effective Diabetes Medications Expands Market for Generic Inhibitors
    • Rising Obesity Rates Globally Propel Growth of Antidiabetic Medications
    • Increasing Focus on Improving Glycemic Control Sustains Demand for Alpha Glucosidase Inhibitors
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Alpha Glucosidase Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Alpha Glucosidase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Alpha Glucosidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Type 2 Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Type 2 Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Type 2 Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dumping Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dumping Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dumping Syndrome Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • JAPAN
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • CHINA
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • EUROPE
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Alpha Glucosidase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Alpha Glucosidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • FRANCE
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • GERMANY
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Alpha Glucosidase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Alpha Glucosidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • INDIA
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Alpha Glucosidase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Alpha Glucosidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Alpha Glucosidase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Alpha Glucosidase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030
  • AFRICA
    • Alpha Glucosidase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Alpha Glucosidase Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Alpha Glucosidase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Alpha Glucosidase Inhibitors by Application - Type 2 Diabetes Application and Dumping Syndrome Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Alpha Glucosidase Inhibitors by Application - Percentage Breakdown of Value Sales for Type 2 Diabetes Application and Dumping Syndrome Application for the Years 2014, 2024 & 2030

IV. COMPETITION